Polyethylene glycol loxenatide Active substance Polyethylene glycol loxenatideDomain Metabolism and EndocrinologyReason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)Main indication DiabetesExtended indication In combination with metformin in patients with type 2 diabetes mellitus. 1. Product Manufacturer Jiangsu HengruiMechanism of action GLP-1 receptor agonistRoute of administration SubcutaneousTherapeutical formulation InjectionBudgetting framework Extramural (GVS)Additional comments GLP-1 Receptor Agonist Bekostiging mogelijk extramuraal conform andere glp-1 agonisten 2. Registration Registration route Centralised (EMA)Submission date 2020Expected Registration 2021Orphan drug NoRegistration phase Clinical trialsAdditional comments Verwachte indiening gebaseerd op actual primary completion date fase 3 studie in datum in 2016. 3. Therapeutic value Current treatment options Andere GLP1-agonisten.Therapeutic value No judgementFrequency of administration 1 times a weekDosage per administration 100µgReferences NCT02477969 4. Expected patient volume per year References GIPdatabankAdditional comments Totale GLP-1 klasse in 2017 volgens GIP 12.919 gebruikers. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension There is currently nothing known about indication extensions. 9. Other information There is currently no futher information available.